Cargando…

Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis

Peptide immunocortin sequence corresponds to the amino acid residues 11–20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggest...

Descripción completa

Detalles Bibliográficos
Autores principales: Turobov, Valery I., Danilkovich, Alexey V., Shevelev, Alexei B., Biryukova, Yulia K., Pozdniakova, Natalia V., Azev, Viatcheslav N., Murashev, Arkady N., Lipkin, Valery M., Udovichenko, Igor P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829527/
https://www.ncbi.nlm.nih.gov/pubmed/29527165
http://dx.doi.org/10.3389/fphar.2018.00113
_version_ 1783302823296892928
author Turobov, Valery I.
Danilkovich, Alexey V.
Shevelev, Alexei B.
Biryukova, Yulia K.
Pozdniakova, Natalia V.
Azev, Viatcheslav N.
Murashev, Arkady N.
Lipkin, Valery M.
Udovichenko, Igor P.
author_facet Turobov, Valery I.
Danilkovich, Alexey V.
Shevelev, Alexei B.
Biryukova, Yulia K.
Pozdniakova, Natalia V.
Azev, Viatcheslav N.
Murashev, Arkady N.
Lipkin, Valery M.
Udovichenko, Igor P.
author_sort Turobov, Valery I.
collection PubMed
description Peptide immunocortin sequence corresponds to the amino acid residues 11–20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggested that immunocortin administering may be of use for patients with self-immune syndrome. Immunocortin in concentration 10 μM inhibited proliferation of both antigen (myelin)-induced and ConA-induced LN lymphocytes isolated from the lymph nodes of Dark Agouti (DA) rats immunized with chorda shear. The biological trials of the synthetic immunocortin were carried out on the DA rats with induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. These in vivo experiments have shown that intraperitoneal injections of immunocortin in a daily dosage 100 μg per animal reduced symptoms of EAE in DA rats.
format Online
Article
Text
id pubmed-5829527
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58295272018-03-09 Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis Turobov, Valery I. Danilkovich, Alexey V. Shevelev, Alexei B. Biryukova, Yulia K. Pozdniakova, Natalia V. Azev, Viatcheslav N. Murashev, Arkady N. Lipkin, Valery M. Udovichenko, Igor P. Front Pharmacol Pharmacology Peptide immunocortin sequence corresponds to the amino acid residues 11–20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggested that immunocortin administering may be of use for patients with self-immune syndrome. Immunocortin in concentration 10 μM inhibited proliferation of both antigen (myelin)-induced and ConA-induced LN lymphocytes isolated from the lymph nodes of Dark Agouti (DA) rats immunized with chorda shear. The biological trials of the synthetic immunocortin were carried out on the DA rats with induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. These in vivo experiments have shown that intraperitoneal injections of immunocortin in a daily dosage 100 μg per animal reduced symptoms of EAE in DA rats. Frontiers Media S.A. 2018-02-23 /pmc/articles/PMC5829527/ /pubmed/29527165 http://dx.doi.org/10.3389/fphar.2018.00113 Text en Copyright © 2018 Turobov, Danilkovich, Shevelev, Biryukova, Pozdniakova, Azev, Murashev, Lipkin and Udovichenko. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Turobov, Valery I.
Danilkovich, Alexey V.
Shevelev, Alexei B.
Biryukova, Yulia K.
Pozdniakova, Natalia V.
Azev, Viatcheslav N.
Murashev, Arkady N.
Lipkin, Valery M.
Udovichenko, Igor P.
Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis
title Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis
title_full Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis
title_fullStr Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis
title_full_unstemmed Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis
title_short Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis
title_sort efficacy of synthetic peptide corresponding to the acth-like sequence of human immunoglobulin g1 in experimental autoimmune encephalomyelitis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829527/
https://www.ncbi.nlm.nih.gov/pubmed/29527165
http://dx.doi.org/10.3389/fphar.2018.00113
work_keys_str_mv AT turobovvaleryi efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT danilkovichalexeyv efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT shevelevalexeib efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT biryukovayuliak efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT pozdniakovanataliav efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT azevviatcheslavn efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT murashevarkadyn efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT lipkinvalerym efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis
AT udovichenkoigorp efficacyofsyntheticpeptidecorrespondingtotheacthlikesequenceofhumanimmunoglobuling1inexperimentalautoimmuneencephalomyelitis